Literature DB >> 24216234

Optimization of interferon gamma ELISPOT assay to detect human cytomegalovirus specific T-cell responses in solid organ transplants.

Davide Abate1, Alda Saldan2, Gabriella Forner2, Daniel Tinto2, Alice Bianchin2, Giorgio Palù2.   

Abstract

Assessing the CMV specific CMI in transplant subjects represents a promising strategy to determine the risk of infection on individual basis. In this study 61 adult CMV IgG seropositive solid organ transplant recipients were examined in order to improve the efficacy of CMI detection. For this purpose, pair-wise comparisons were conducted comparing positive control stimuli PWM and PMA/iono and CMV stimuli, pp65 peptide pool and whole CMV particle. Rosette pre-depletion of blood was also investigated for detecting CD4+ or CD8+ T-cell responses using the IFN-g ELISPOT assay. In the time-points 30-180 days after transplantation, PMA/iono produced statistically significant higher responses compared to PWM, probably because PMA/iono activation pathway is independent from the effect of immunosuppressive drugs. The data showed that 11% of transplant patients displayed very low or undetectable responses to pp65 peptide pool antigen while having sustained high responses to whole CMV particle. In addition, in all the subjects analyzed, CMI responses to CMV particle produced a statistically significant higher number of spots compared to pp65 peptide pool antigen. Rosette pre-depletion of whole blood proved to be effective in detecting CD4+ or CD8+ T-cell responses similarly to flow cytometry. Taken together, the following recommendations are suggested to optimize the CMV-ELISPOT for transplantation settings: (1) use PMA/iono as positive control; (2) whole virus particle should be used to avoid peptide-related false negative responses; (3) a rosette pre-depletion step may be useful to detect CD4+ or CD8+ T-cell responses.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AZA; CMI; CMV; Cell mediated immunity; ConA; CsA; ELISPOT; HLA; Human cytomegalovirus; Interferon gamma releasing assay; MMF; PBMCs; PFU; PHA; PKC; PMA/iono; PWM; T-cell; Transplantation; azathioprine; cell-mediated immunity; concanavalin A; cyclosporine A; human cytomegalovirus; human leukocyte antigen; mycophenolic acid; peripheral blood mononuclear cells; phorbol myristate acetate and ionomycin; phytohemoagglutinin; plaque forming unit; pokeweed mitogen; protein kinase C

Mesh:

Substances:

Year:  2013        PMID: 24216234     DOI: 10.1016/j.jviromet.2013.10.036

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  6 in total

1.  Modification of the HCMV-specific IFN-γ release test (QuantiFERON-CMV) and a novel proposal for its application.

Authors:  Takahiro Kobayashi; Jun-Ichi Sato; Kazufumi Ikuta; Ryoko Kanno; Kyoko Nishiyama; Tetsuo Koshizuka; Ken Ishioka; Tatsuo Suzutani
Journal:  Fukushima J Med Sci       Date:  2017-06-22

2.  Comparison of the Cytomegalovirus (CMV) Enzyme-Linked Immunosorbent Spot and CMV QuantiFERON Cell-Mediated Immune Assays in CMV-Seropositive and -Seronegative Pregnant and Nonpregnant Women.

Authors:  Alda Saldan; Gabriella Forner; Carlo Mengoli; Daniel Tinto; Loredana Fallico; Marta Peracchi; Nadia Gussetti; Giorgio Palù; Davide Abate
Journal:  J Clin Microbiol       Date:  2016-03-09       Impact factor: 5.948

Review 3.  Testing for Cytomegalovirus in Pregnancy.

Authors:  Alda Saldan; Gabriella Forner; Carlo Mengoli; Nadia Gussetti; Giorgio Palù; Davide Abate
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

4.  Surveillance of γδ T Cells Predicts Cytomegalovirus Infection Resolution in Kidney Transplants.

Authors:  Hannah Kaminski; Isabelle Garrigue; Lionel Couzi; Benjamin Taton; Thomas Bachelet; Jean-François Moreau; Julie Déchanet-Merville; Rodolphe Thiébaut; Pierre Merville
Journal:  J Am Soc Nephrol       Date:  2015-06-08       Impact factor: 10.121

5.  Cytomegalovirus (CMV) Enzyme-Linked Immunosorbent Spot Assay but Not CMV QuantiFERON Assay Is a Novel Biomarker To Determine Risk of Congenital CMV Infection in Pregnant Women.

Authors:  Gabriella Forner; Alda Saldan; Carlo Mengoli; Nadia Gussetti; Giorgio Palù; Davide Abate
Journal:  J Clin Microbiol       Date:  2016-06-08       Impact factor: 5.948

6.  An optimized IFN-γ ELISpot assay for the sensitive and standardized monitoring of CMV protein-reactive effector cells of cell-mediated immunity.

Authors:  Sascha Barabas; Theresa Spindler; Richard Kiener; Charlotte Tonar; Tamara Lugner; Julia Batzilla; Hanna Bendfeldt; Anne Rascle; Benedikt Asbach; Ralf Wagner; Ludwig Deml
Journal:  BMC Immunol       Date:  2017-03-07       Impact factor: 3.615

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.